{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Overall survival time was defined as the time from randomization to death. Subjects without events were censored at the last date they were known to be alive.","groups":[{"description":"Subjects who received tecemotide in a feeder study continued treatment with tecemotide and had safety assessments performed until the discontinuation criteria described in the respective feeder study protocol were met. Once the subject discontinued maintenance treatment, an End of Treatment visit was performed. Thereafter, the subjects were observed for progression of disease (PD) (if applicable according to the respective feeder study protocol) and survival in 6-month intervals.","id":"OG000","title":"Non-small Cell Lung Cancer (NSCLC)"},{"description":"Subjects who received tecemotide in a feeder study continued treatment with tecemotide and had safety assessments performed until the discontinuation criteria described in the respective feeder study protocol were met. Once the subject discontinued maintenance treatment, an End of Treatment visit was performed. Thereafter, the subjects were observed for progression of disease (PD) (if applicable according to the respective feeder study protocol) and survival in 6-month intervals.","id":"OG001","title":"Multiple Myeloma"}],"populationDescription":"Efficacy analysis was not performed due to the premature termination of this safety follow-up study and the tecemotide program based on negative results in EMR 63325-009 (NCT00960115)","reportingStatus":"POSTED","timeFrame":"From randomization to death, assessed up to 3.6 years","title":"Overall Survival (OS)","type":"SECONDARY"}